855 Dermal exposure to diisocyanates: development and validation of an analytical method for accurately assessment of very low levels of exposure

    loading  Checking for direct PDF access through Ovid


IntroductionDermal exposure to sensitizers such as diisocyanate have been described to promote the development of asthma in later stages when respiratory occupational exposure occurs. Therefore, we developed a reliable, sensitive and validated methodology based on dermal patches to assess skin exposure to diisocyanates.MethodsAn UPLC-Unispray-MS/MS method was established and validated in order to reach very low levels of detection. Custom-made dermal patches were developed in order to allow optimal sampling of diisocyanates. Their sampling capability was evaluated in a controlled environment test-chamber were patches were exposed to increasing concentrations of diisocyanates.ResultThe UPLC-MS/MS method using a Unispray ionisation source, based on supercritical fluids ionisation and Coanda effect, allowed reaching very low levels of detection (LoD=1 pg/mL) for all the targeted compounds (i.e. 4,4-MDI, 2,4-MDI, 2,6-TDI, 2,4-TDI, 1,6-HDI, and IPDI). Due to the high sensitivity of the analytical method, very low levels of diisocyanates (i.e. 25 pg/patch) are detected on the custom-made dermal patches. Furthermore, the patches allowed the sampling of a broad range of concentration levels (from 5 pg/cm2 to 5 ng/cm2), which have been correlated with the air levels from the controlled environment chamber-test.DiscussionWe succeeded to develop a method to assess dermal exposure to diisocyanates. Field studies are now necessary to further evaluate the suitability of the custom-made patches, as well as to relate low levels of exposure and potential health outcomes.

    loading  Loading Related Articles